Physician profile
Cherryl Thomas
NPI 1134113640
$1,239.56
in general payments reported to CMS, 2019-2025
22 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.15 · 2020: $23.82 · 2021: $28.09 · 2022: $314 · 2023: $387 · 2024: $265 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.86 | 2019-2024 | Jardiance |
| Abbvie INC. | $104.30 | 2022-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $93.52 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $93.10 | 2023 | Otezla, Repatha |
| Lilly USA, LLC | $83.69 | 2022-2023 | Mounjaro, Jardiance, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.40 | 2022-2024 | Caplyta |
| Axogen | $76.00 | 2025 | Axoguard Ha+ Nerve Protector |
| Astrazeneca Pharmaceuticals Lp | $72.92 | 2022-2025 | Airsupra |
| Abbott Laboratories | $69.87 | 2022-2024 | Freestyle Libre 3 |
| Genentech USA, INC. | $59.34 | 2024 | Xolair |
| Biohaven Pharmaceutical Holding Company Ltd. | $52.35 | 2022 | |
| Pfizer INC. | $44.79 | 2023-2025 | |
| Neos Therapeutics, Lp | $40.93 | 2022 | |
| Idorsia Pharmaceuticals US INC | $30.85 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $29.57 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $29.27 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $27.16 | 2022 | |
| Sanofi-Aventis U.S. LLC | $25.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.49 | 2024 | |
| Merck Sharp & Dohme LLC | $15.89 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Corium, LLC | $15.75 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $15.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherryl Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.